CXCR1/IL-8RA Antibody (42709) [DyLight 488]
Novus Biologicals, part of Bio-Techne | Catalog # FAB3302K
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
CyTOF-ready, Flow Cytometry
Label
DyLight 488 (Excitation = 493 nm, Emission = 518 nm)
Antibody Source
Recombinant Monoclonal Mouse IgG2A Clone # 42709
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
NS0 mouse myeloma cell line transfected with human CXCR1/IL-8 RA
Met1-Leu350
Accession # AAA59159
Met1-Leu350
Accession # AAA59159
Specificity
Detects human CXCR1/IL-8RA in direct ELISAs.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2A
Applications for CXCR1/IL-8RA Antibody (42709) [DyLight 488]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CXCR1/IL-8RA
Long Name
Interleukin 8 Receptor A
Alternate Names
CD181, IL-8 RA, IL8RA
Additional CXCR1/IL-8RA Products
Product Documents for CXCR1/IL-8RA Antibody (42709) [DyLight 488]
Product Specific Notices for CXCR1/IL-8RA Antibody (42709) [DyLight 488]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...